Insulin icodec has been submitted for regulatory review in the United States, Canada, Europe, China, Australia, Switzerland, and Brazil, with decisions anticipated starting in the first half of 2024.
In ONWARDS 1, in contrast, sulfonylureas and glinides were stopped at the time of randomization."That's not definitive, but I would argue that's the explanation, to be proven by formal testing." The percentage of time in blood glucose range was also significantly higher with icodec than glargine , also confirming superiority.
ONWARDS 3 randomized 588 patients each to once-weekly insulin icodec plus once-weekly placebo or once-daily
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Bitcoin Investment Sentiment Turned Bullish After Largest Weekly Fund Inflow in a YearDigital asset investment products witnessed the largest single weekly inflows in a year - mostly dominated by bitcoin-related products - after nine consecutive weeks of outflows, according to CoinSharesCo research. LedesmaLyllah reports.
ソース: CoinDesk - 🏆 291. / 63 続きを読む »
Crypto investment products see largest weekly inflow since July 2022CoinShares' weekly inflows report arrives with good news as crypto investment products see their highest inflows in nearly a year on the back of a Bitcoin-led rally with nearly $200 million in inflows. These rallies come after Bitcoin dropped below $25,000 in June for the first time since mid-March after the United States Securities and Exchange Commission leveled separate lawsuits against Binance and Coinbase alleging improprieties.
ソース: Cointelegraph - 🏆 562. / 51 続きを読む »